| Bioactivity | DETQ is a selective, allosteric and orally active dopamine D1 receptor (Dopamine Receptor) potentiator. In HEK293 cells expressing the human D1 receptor, DETQ increases cAMP with an EC50 of 5.8 nM and a Kb of 26 nM. DETQ shows ~30-fold less potent at rat and mouse D1 receptors and is inactive at the human D5 receptor[1]. |
| In Vivo | DETQ (10 mg/kg；腹腔注射；一次) 改善雄性人源化 D1 受体敲入小鼠的亚慢性 Phencyclidine 诱导的物体识别记忆缺陷并增强皮质乙酰胆碱流出[2]。 Animal Model: |
| Name | DETQ |
| CAS | 1638667-81-8 |
| Formula | C22H25Cl2NO3 |
| Molar Mass | 422.34 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Kjell A Svensson, et al. An Allosteric Potentiator of the Dopamine D1 Receptor Increases Locomotor Activity in Human D1 Knock-In Mice without Causing Stereotypy or Tachyphylaxis. J Pharmacol Exp Ther. 2017 Jan;360(1):117-128. [2]. Herbert Y Meltzer, et al. The allosteric dopamine D1 receptor potentiator, DETQ, ameliorates subchronic phencyclidine-induced object recognition memory deficits and enhances cortical acetylcholine efflux in male humanized D1 receptor knock-in mice. Behav Brain Res. 2019 Apr 1;361:139-150. |